Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Oncogene

• Publication date

  2005-11-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1209041PMID 16299532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The preferential cytotoxicity of reovirus for certain transformed cell lines

  2005cited by this paper
• The implications of structured 5' untranslated regions on translation and disease.

  2005cited by this paper
• Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals

  2004cited by this paper
• Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

  2004cited by this paper
• Structural organization of mRNA complexes with major core mRNP protein YB-1.

  2004cited by this paper
• Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.

  2004influential reference
• High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus

  2004cited by this paper
• Targets and mechanisms for the regulation of translation in malignant transformation

  2004cited by this paper
• Replicating adenoviruses in cancer therapy.

  2004cited by this paper
• Oncogenic Ras and its role in tumor cell invasion and metastasis.

  2004cited by this paper
• Defective translational control facilitates vesicular stomatitis virus oncolysis.

  2004cited by this paper
• Interferon resistance promotes oncolysis by influenza virus NS1‐deletion mutants

  2004cited by this paper
• Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

  2004cited by this paper
• Transcriptional upregulation of interferon-induced protein kinase, PKR, in breast cancer.

  2003cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• Ral-GTPases: approaching their 15 minutes of fame.

  2003cited by this paper
• Reovirus Oncolysis of Human Breast Cancer

  2002cited by this paper
• Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

  2002cited by this paper
• Growth factors can activate ATF2 via a two‐step mechanism: phosphorylation of Thr71 through the Ras–MEK–ERK pathway and of Thr69 through RalGDS–Src–p38

  2002cited by this paper
• Replication-selective viruses for cancer therapy

  2002cited by this paper
• Cell signaling: life or death decisions of ras proteins.

  2002cited by this paper
• Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice.

  2001cited by this paper
• Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1

  2001cited by this paper
• To cycle or not to cycle: a critical decision in cancer

  2001cited by this paper
• A genetically engineered influenza A virus with ras-dependent oncolytic properties.

  2001cited by this paper
• Translational Silencing of Ceruloplasmin Requires the Essential Elements of mRNA Circularization: Poly(A) Tail, Poly(A)-Binding Protein, and Eukaryotic Translation Initiation Factor 4G

  2001cited by this paper
• Antiviral Actions of Interferons

  2001cited by this paper
• An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

  2000cited by this paper
• The Ras branch of small GTPases: Ras family members don't fall far from the tree.

  2000cited by this paper
• Conditionally replicating herpes vectors for cancer therapy.

  2000cited by this paper
• Identification of Carbohydrate-Binding Domains in the Attachment Proteins of Type 1 and Type 3 Reoviruses

  2000cited by this paper
• Cellular receptors for viruses: links to tropism and pathogenesis.

  2000cited by this paper
• Newcastle disease virus (NDV): brief history of its oncolytic strains.

  2000cited by this paper
• Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.

  2000cited by this paper
• p38 MAPK signalling cascades: ancient roles and new functions

  2000cited by this paper
• Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

  2000cited by this paper
• Reovirus as a novel oncolytic agent.

  2000cited by this paper
• Translational control: the cancer connection.

  1999cited by this paper
• Ras caught in another affair: the exchange factors for Ral.

  1999cited by this paper
• Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis and fas receptor expression.

  1999cited by this paper
• Translational control of growth factor and proto-oncogene expression.

  1999cited by this paper
• PKR, apoptosis and cancer.

  1999cited by this paper
• Double-Stranded-RNA-Activated Protein Kinase PKR Enhances Transcriptional Activation by Tumor Suppressor p53

  1999cited by this paper
• Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins.

  1999cited by this paper
• Increasing complexity of Ras signaling

  1998influential reference
• Switching signals on or off by receptor dimerization.

  1998cited by this paper
• Reovirus therapy of tumors with activated Ras pathway.

  1998cited by this paper
• Nuclear history of a pre‐mRNA determines the translational activity of cytoplasmic mRNA

  1998cited by this paper
• Regulation of translational initiation during cellular responses to stress.

  1998cited by this paper
• The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.

  1998cited by this paper
• The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

  1998influential reference
• Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF‐1 and NF‐κB

  1997cited by this paper
• Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

  1997cited by this paper
• Signaling through scaffold, anchoring, and adaptor proteins.

  1997cited by this paper
• Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras.

  1997cited by this paper
• Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1

  1997cited by this paper
• Ras effectors.

  1996cited by this paper
• A Role for the Ral Guanine Nucleotide Dissociation Stimulator in Mediating Ras-induced Transformation*

  1996cited by this paper
• Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation

  1996cited by this paper
• The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection

  1996cited by this paper
• The eIF‐2α kinases and the control of protein synthesis 1

  1996cited by this paper
• Guanine nucleotide exchange factors: Activators of Ras superfamily proteins

  1995cited by this paper
• Multiple Ras functions can contribute to mammalian cell transformation.

  1995cited by this paper
• Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene

  1995cited by this paper
• Molecular Mechanisms Responsible for Malignant Transformation by Regulatory and Catalytic Domain Variants of the Interferon-induced Enzyme RNA-dependent Protein Kinase (*)

  1995cited by this paper
• Abrogation of translation initiation factor eIF‐2 phosphorylation causes malignant transformation of NIH 3T3 cells.

  1995cited by this paper
• SH2 and SH3 domains in signal transduction.

  1994cited by this paper
• Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells.

  1994cited by this paper
• eIF-2 kinases: regulators of general and gene-specific translation initiation.

  1994cited by this paper
• Storage of messenger RNA in eukaryotes: Envelopment with protein, translational barrier at 5′ side, or conformational masking by 3′ side?

  1994cited by this paper
• Cells and viruses with mutations affecting viral entry are selected during persistent infections of L cells with mammalian reoviruses

  1993cited by this paper
• Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.

  1993cited by this paper
• Signalling by receptor tyrosine kinases.

  1993cited by this paper
• Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase.

  1993cited by this paper
• Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2.

  1992cited by this paper
• Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase.

  1992cited by this paper
• Role of cytoplasmic mRNP proteins in translation.

  1992cited by this paper
• Molecular oncology

  1991cited by this paper
• A sigma 1 region important for hemagglutination by serotype 3 reovirus strains

  1990cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Mechanism of interferon action. Activation of the human P1/eIF-2 alpha protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA.

  1989cited by this paper
• Inhibition of reovirus type 3 binding to host cells by sialylated glycoproteins is mediated through the viral attachment protein

  1987cited by this paper
• Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease

  1985cited by this paper
• Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes.

  1984cited by this paper
• Selection of a mutant S1 gene during reovirus persistent infection of L cells: role in maintenance of the persistent state.

  1983cited by this paper
• Role of the host cell in persistent viral infection: coevolution of L cells and reovoirus during persistent infection.

  1981cited by this paper
• Differential sensitivity of normal and transformed human cells to reovirus infection

  1978cited by this paper

• Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection

  2026cites this paper
• Spatiotemporal coordination of reovirus peripheral core replication to perinuclear whole virus assembly

  2025cites this paper
• Oncolytic viruses in cancer therapy: Exploring the mechanisms and clinical potential of mammalian and avian reoviruses

  2025cites this paper
• Experimental models for developing oncolytic virotherapy for metastatic prostate cancer

  2025cites this paper
• The Abundance of KRAS and RAS Gene Mutations in Cancer.

  2024cites this paper
• Screening and verification of differentially expressed serum proteins in children with severe adenovirus pneumonia

  2024cites this paper
• Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape

  2024cites this paper
• Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer

  2024cites this paper
• Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy

  2024cites this paper
• Modulation of Reoviral Cytolysis (II): Cellular Stemness

  2023cites this paper
• Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment

  2023cites this paper
• Development and application of oncolytic viruses as the nemesis of tumor cells

  2023cites this paper
• Radiotherapy/Chemotherapy-Immunotherapy for Cancer Management: From Mechanisms to Clinical Implications

  2023cites this paper
• Pteropine Orthoreovirus, PRV7S (Sikamat Virus) Demonstrates Oncolysis in Nasopharyngeal Carcinoma Cell Lines.

  2022cites this paper
• Genetic Modifications That Expand Oncolytic Virus Potency

  2022cites this paper
• Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions

  2022cites this paper
• Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

  2022cites this paper
• Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy

  2022cites this paper
• Reovirus uses temporospatial compartmentalization to orchestrate core versus outercapsid assembly

  2022cites this paper
• Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy

  2022cites this paper
• A Single Point Mutation, Asn16→Lys, Dictates the Temperature-Sensitivity of the Reovirus tsG453 Mutant

  2021cites this paper
• A Single Point Mutation , Asn 16 → Lys , Dictates the Temperature ‐ Sensitivity of the Reovirus tsG 453 Mutant

  2021cites this paper
• Oncolytic Virotherapy: From Bench to Bedside

  2021cites this paper
• Therapeutic Approach to KRAS Mutated Colorectal Cancer

  2021cites this paper
• Induction of Robust Type I Interferon Levels by Oncolytic Reovirus Requires Both Viral Replication and Interferon-α/β Receptor Signaling

  2021cites this paper
• Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy

  2021cites this paper
• Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis

  2021cites this paper
• Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

  2020cites this paper
• Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials

  2020cites this paper
• Past, Present and Future of Oncolytic Reovirus

  2020cites this paper
• Closely related reovirus lab strains induce opposite expression of RIG-I/IFN-dependent versus -independent host genes, via mechanisms of slow replication versus polymorphisms in dsRNA binding σ3 respectively

  2020cites this paper
• Oncolytic Viruses in Tumorigenic Pathways

  2020cites this paper
• Targeted Identification of Protein Interactions in Eukaryotic mRNA Translation

  2020cites this paper
• DEVELOPING NATURAL KILLER T CELL BASED TOOLS AND STRATEGIES FOR TARGETING BREAST CANCER

  2019cites this paper
• Genetic Polymorphisms and Molecular Mechanisms Mediating Oncolytic Potency of Reovirus Strains

  2019cites this paper
• Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?

  2019cites this paper
• Oncolytic reovirus shows potentially anticancer effect against CT26 cell lines

  2019cites this paper
• Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and In Vivo

  2019cites this paper
• Potentiating prostate cancer immunotherapy with oncolytic viruses

  2018cites this paper
• Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

  2017cites this paper
• Development of oncolytic virotherapy for the treatment of oral cancer – At the waiting stage for clinical use

  2017cites this paper
• Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

  2017cites this paper
• NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy

  2017cites this paper
• Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.

  2017cites this paper
• Evolution of Reovirus in Cancer Therapy

  2017cites this paper
• Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

  2016cites this paper
• Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release

  2016cites this paper
• Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection

  2016cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus

  2016cites this paper
• Viruses and Head and Neck Cancers

  2016cites this paper
• Comparative Study of Colon Cancer Subclones Uncovers Potential Roles for AKAP7 and TP53RK in the Antiviral Response.

  2016cites this paper
• Optimising Reovirus Type 3 Dearing (Reolysin®) as an anti-cancer therapeutic

  2016cites this paper
• Combinaison d’approches classiques et de génétique inverse en vue d'une meilleure compréhension du tropisme et de l'activité oncolytique du réovirus de mammifères

  2015cites this paper
• Oncolytic viruses: From bench to bedside with a focus on safety

  2015cites this paper
• Reovirus oncolysis-Role of cyclin-dependent kinase inhibitor 1

  2015cites this paper
• Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma

  2015cites this paper
• mammalian reoviruses for use as

  2015cites this paper
• Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

  2015cites this paper
• Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy

  2015cites this paper
• Oncolytic Newcastle Disease Virus as treatment for pancreatic cancer

  2015cites this paper
• The oncolytic effects of reovirus in canine solid tumor cell lines

  2015cites this paper
• The oncolytic virus, pelareorep, as a novel anticancer agent: a review

  2015cites this paper
• Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan

  2014cites this paper
• Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by KRAS Activity

  2014cites this paper
• Reovirus in cancer therapy: an evidence-based review

  2014cites this paper
• Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells

  2014influential citation
• Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

  2014cites this paper
• Permissiveness of human cancer cells to oncolytic Bovine herpes virus type 1 is mediated in 1 part by KRAS activity

  2014cites this paper
• Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature

  2014cites this paper
• Exploiting tumor epigenetics to improve oncolytic virotherapy

  2013cites this paper
• Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression

  2013cites this paper
• Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer

  2013cites this paper
• Étude de la protéine sigma 1 de réovirus par génétique inverse

  2012influential citation
• Reovirus Uses Multiple Endocytic Pathways for Cell Entry

  2012cites this paper
• Reovirus: A Targeted Therapeutic—Progress And Potential

  2012influential citation
• Immune mediated and direct killing of colorectal cancer by reovirus

  2012cites this paper
• Oncolytic Bluetongue Viruses: Promise, Progress, and Perspectives

  2011influential citation
• Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer.

  2011cites this paper
• Oncolytic virus-initiated protective immunity against prostate cancer.

  2011cites this paper
• Assessing the components of the eIF3 complex and their phosphorylation status.

  2011cites this paper
• Oncolytic Virotherapy of Cancer

  2011cites this paper
• Assessing the Mechanism of Reovirus Oncolysis

  2011cites this paper
• Biological Effects of a De Novo Designed Myxoma Virus Peptide Analogue: Evaluation of Cytotoxicity on Tumor Cells

  2011cites this paper
• IDENTIFICATION AND CHARACTERIZATION OF GENES ESSENTIAL FOR ONCOLYTIC NEWCASTLE DISEASE VIRUS REPLICATION IN HUMAN TUMOR CELLS

  2010cites this paper
• Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity

  2010cites this paper
• Molecular Cancer apeutics apeutic Discovery virus Virotherapy Overrides Tumor Antigen Presentation Ther sion and Promotes Protective Antitumor Immunity

  2010cites this paper
• Reovirus-based therapy for cancer

  2009cites this paper
• Modification of mammalian reoviruses for use as oncolytic agents

  2009cites this paper
• Chapter 9 Viral Strategies to Subvert the Mammalian Translation Machinery

  2009cites this paper
• Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

  2008cites this paper
• Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

  2008cites this paper
• A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting

  2008cites this paper
• Efficacy of oncolytic reovirus against human breast cancer cells.

  2008cites this paper
• Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

  2008cites this paper
• Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

  2008cites this paper
• Reovirus therapy in cancer: has the orphan virus found a home?

  2008cites this paper
• Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?

  2008cites this paper
• Silencing and complementation of reovirus core protein mu2: functional correlations with mu2-microtubule association and differences between virus- and plasmid-derived mu2.

  2007cites this paper
• REOVIRUS ONCOLYSIS: A BRIEF INSIGHT ON MOLECULAR MECHANISM AND IMMUNOLOGICAL ASPECT

  2007cites this paper